Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

Home CompaniesVeru Inc

Veru Inc

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
2.12 USD 0.06 ( 2.91%)
Last update at 2026-11-06T21:00:00Z
VOLUME
137140
Market Cap
174.20M

Momentum Score

…

Veru Inc., a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections. The company's development program includes enobosarm, a selective androgen receptor modulator for treatment of augment fat loss and to prevent muscle loss in sarcopenic obese and overweight elderly patients; Enobosarm, a selective androgen receptor modulator for the treatment of AR+ ER+ HER2- metastatic breast cancer; and sabizabulin, a microtubule disruptor for the treatment of hospitalized patients with viral lung infection on oxygen support who are at high risk for viral induced ARDS and death. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. was incorporated in 1971 and is headquartered in Miami, Florida.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
2.06
Low
2.15
High
52 Week Price Range
0.36
Low
1.92
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Veru Inc is a clinical-stage biopharmaceutical company developing therapeutics in oncology and infectious disease, advancing candidates through clinical trials toward regulatory approval. Long-term growth may be driven by positive trial outcomes, successful regulatory decisions, and business development or licensing that could support commercialization, which may make the company attractive to investors seeking biotech upside.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
2.06
Dividend Yield
-
Revenue TTM
13.48M
Revenue Per Share
0.13
Gross Profit TTM
30.59M
Debt / Equity
0.81
ROE
-125.82%
Net Debt
4.78M
ROCE
-313.25%
Diluted EPS TTM
-0.35

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2023-09-30 2022-09-30 2021-09-30 2020-09-30 2019-09-30
Type yearly yearly yearly yearly yearly
Date 2023-09-30 2022-09-30 2021-09-30 2020-09-30 2019-09-30
Income before tax -92.61M -83.54M 4.27M -20.05M -12.32M
Net income -93.09M -83.78M 7.39M -18.97M -12.02M
Selling general administrative 48.06M 43.17M 20.67M 14.50M 14.35M
Gross profit 7.57M 30.59M 47.93M 30.79M 21.66M
Reconciled depreciation 0.27M 0.21M 0.21M 0.46M 0.47M
Ebit -94.97M -83.43M -5.44M -15.21M -6.91M
Ebitda -94.70M -83.22M -23.85M -14.75M -6.44M
Depreciation and amortization 0.27M 0.21M -18.41M 0.46M 0.47M
Non operating income net other - 4.05M -3.82M -0.68M -1.18M
Operating income -93.72M -83.22M -5.44M -14.75M -6.44M
Other operating expenses 111.84M 122.58M 66.70M 57.34M 38.24M
Interest expense 2.43M 4.37M 4.85M 4.62M 4.71M
Tax provision 0.48M 0.24M -3.13M -1.08M -0.30M
Interest income - - - - 5.89M
Net interest income -2.43M -4.37M -4.89M -4.62M -4.71M
Non recurring - - - 14.10M -
Income tax expense 0.48M 0.24M -3.13M -1.08M -0.30M
Total revenue 16.30M 39.35M 61.26M 42.59M 31.80M
Total operating expenses 103.11M 113.81M 53.36M 45.53M 28.09M
Cost of revenue 8.73M 8.76M 13.33M 11.81M 10.15M
Total other income expense net 5.36M -0.32M 9.70M -5.31M -5.89M
Net income from continuing ops -93.09M -83.78M 7.39M -18.97M -12.02M
Net income applicable to common shares - -83.78M 7.39M -18.97M -12.02M
Breakdown 2023-09-30 2022-09-30 2021-09-30 2020-09-30 2019-09-30
Type yearly yearly yearly yearly yearly
Date 2023-09-30 2022-09-30 2021-09-30 2020-09-30 2019-09-30
Total assets 50.60M 136.13M 178.15M 51.54M 53.63M
Intangible assets 0.01M 3.98M 4.05M 5.75M 20.17M
Other current assets 1.10M 12.41M 15.03M 1.49M 1.84M
Total liab 32.81M 55.29M 25.85M 21.43M 21.30M
Total stockholder equity 17.78M 80.84M 152.29M 30.11M 32.33M
Deferred long term liab - 0.08M 0.06M 0.07M 0.30M
Other current liab 4.67M 18.27M 9.12M 1.10M 5.51M
Common stock 0.94M 0.83M 0.82M 0.72M 0.67M
Capital stock 0.94M 0.83M 0.82M 0.72M 0.67M
Retained earnings -258.66M -165.57M -81.80M -89.19M -70.22M
Other liab - 0.10M 0.08M 0.09M 0.54M
Good will 6.88M 6.88M 6.88M 6.88M 6.88M
Other assets - 14.53M 13.90M 10.23M 9.42M
Cash 9.63M 80.19M 122.36M 13.59M 6.30M
Total current liabilities 20.28M 41.44M 15.77M 14.73M 14.02M
Current deferred revenue -0.86M - - 3.29M -
Net debt 4.78M -65.27M -109.73M 0.55M 5.82M
Short term debt 1.90M 1.17M 3.24M 7.53M 5.39M
Short long term debt 0.86M 1.17M 3.24M 5.84M 5.39M
Short long term debt total 14.41M 14.92M 12.63M 14.14M 12.12M
Other stockholder equity 276.09M 246.17M 233.85M 119.16M 102.46M
Property plant equipment - 5.97M 0.59M 0.31M 0.35M
Total current assets 23.51M 104.77M 151.75M 27.01M 16.81M
Net tangible assets - 69.98M 141.37M 17.48M 5.29M
Net receivables 4.51M 3.55M 8.79M 5.23M 5.02M
Long term debt 8.87M 9.66M 9.40M 5.62M 2.89M
Inventory 6.70M 8.62M 5.57M 6.70M 3.65M
Accounts payable 14.58M 22.00M 3.41M 2.81M 3.12M
Accumulated other comprehensive income -0.58M -0.58M -0.58M -0.58M -0.58M
Common stock total equity - 0.83M 0.82M 0.72M 0.67M
Retained earnings total equity - -165.57M -81.80M -89.19M -70.22M
Treasury stock - -7.81M -7.81M -7.81M -7.81M
Non currrent assets other 1.51M 1.56M 2.44M 0.77M 0.99M
Non current assets total 27.09M 31.36M 26.39M 24.53M 36.82M
Capital lease obligations 4.67M 5.05M 1.11M 1.58M -
Long term debt total - - - - 2.89M
Breakdown 2023-09-30 2022-09-30 2021-09-30 2020-09-30 2019-09-30
Type yearly yearly yearly yearly yearly
Date 2023-09-30 2022-09-30 2021-09-30 2020-09-30 2019-09-30
Investments 6.33M 4.27M 14.62M -0.11M -0.11M
Change to liabilities - 27.29M 4.85M -1.26M 1.95M
Total cashflows from investing activities - 4.27M 14.62M -0.11M -0.11M
Net borrowings - -0.01M -0.02M -4.42M -4.94M
Total cash from financing activities 11.11M 1.07M 109.72M 9.33M 8.13M
Change to operating activities - 25.88M -4.86M -0.64M 1.49M
Net income -93.09M -83.78M 7.39M -18.97M -12.02M
Change in cash -70.57M -42.17M 108.77M 7.29M 2.54M
Begin period cash flow 80.19M 122.36M 13.59M 6.30M 3.76M
End period cash flow 9.63M 80.19M 122.36M 13.59M 6.30M
Total cash from operating activities -88.01M -47.51M -15.57M -1.93M -5.49M
Issuance of capital stock 6.01M 0.00M 108.10M 0.00M 9.40M
Depreciation 0.27M 0.21M 0.21M 0.46M 0.47M
Other cashflows from investing activities - 4.27M 15.00M -0.11M -0.11M
Change to inventory 0.65M -3.13M 0.55M -3.30M -1.45M
Change to account receivables -4.15M 4.54M -3.56M -0.09M -1.35M
Sale purchase of stock - 1.08M 109.74M -0.05M 13.33M
Other cashflows from financing activities 5.10M 1.08M 1.64M 13.82M 3.66M
Change to netincome - 10.39M -19.95M 20.05M 6.43M
Capital expenditures 0.67M 0.73M 0.38M 0.11M 0.11M
Change receivables - 4.54M -3.56M -0.09M -1.35M
Cash flows other operating - -5.78M -5.06M 1.18M 0.49M
Cash and cash equivalents changes - -42.17M 108.77M 7.29M 2.54M
Change in working capital -15.22M 25.88M -7.28M -4.35M -1.56M
Stock based compensation 17.92M 11.24M 5.05M 2.65M 1.91M
Other non cash items 1.92M -1.14M -17.38M 19.54M 6.16M
Free cash flow -88.68M -48.24M -15.95M -2.04M -5.59M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
VERU
Veru Inc		 0.06
2.91%		 2.12 - 117.65 13.97 4.28 12.22 -3.23
NVO
Novo Nordisk A/S		 0.01
0.02%		 40.31 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 4.59
0.85%		 547.09 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc		 1.45
0.16%		 904.35 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

Veru Inc

Veru Inc., a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections. The company's development program includes enobosarm, a selective androgen receptor modulator for treatment of augment fat loss and to prevent muscle loss in sarcopenic obese and overweight elderly patients; Enobosarm, a selective androgen receptor modulator for the treatment of AR+ ER+ HER2- metastatic breast cancer; and sabizabulin, a microtubule disruptor for the treatment of hospitalized patients with viral lung infection on oxygen support who are at high risk for viral induced ARDS and death. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. was incorporated in 1971 and is headquartered in Miami, Florida.

2916 North Miami Avenue, Miami, FL, United States, 33127

305 509 6897

https://verupharma.com

189

Name Title Year Born
Dr. Mitchell S. Steiner F.A.C.S, F.A.C.S., M.D. Chairman, Pres & CEO 1961
Dr. Harry Fisch F.A.C.S., M.D. Vice Chairman & Chief Corp. Officer 1959
Ms. Michele Greco CFO & Chief Admin. Officer 1959
Dr. K. Gary Barnette Ph.D. Chief Scientific Officer 1968
Mr. Samuel Fisch Exec. Director of Investor Relations & Corp. Communications NA
Mr. Michael J. Purvis Exec. VP, Gen. Counsel & Corp. Strategy and Sec. NA
Mr. Kevin J. Gilbert CPA, J.D. Exec. VP of Corp. Devel. NA
Dr. Domingo Rodriguez M.D. Exec. VP of Global Clinical Operations 1962
Dr. Gary Bird Ph.D. Exec. VP of Quality & Regulatory Affairs NA
Mr. Joel Batten Exec. VP & GM of Infectious Disease Franchise NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

DAR
GBX 8.30
+23.42%
VTY
GBX 276.20
+8.23%
GTCO
GBX 0.09
+6.98%
GLV
GBX 2.34
+6.36%
BUR
GBX 249.20
+5.95%
TMI
GBX 0.72
-6.49%
HSBA
GBX 1291.40
-5.42%
RKT
GBX 5218.00
-4.85%
TGA
GBX 643.00
-4.03%
RKH
GBX 61.70
-3.89%

Equity Sectors*

  • Basic Materials

    -1.70%

  • Communication Services

    +0.33%

  • Consumer Cyclical

    +0.45%

  • Consumer Defensive

    -0.56%

  • Energy

    -0.25%

  • Financial Services

    +0.49%

  • Healthcare

    +0.20%

  • Industrials

    +0.74%

  • Real Estate

    +1.71%

  • Technology

    -2.81%

  • Utilities

    +0.28%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Cookies on this website

We use some essential cookies to make this site work. We also set analytics and marketing cookies, described below, to understand how you use the site and to measure our advertising. For more detailed information, see our Cookie Policy, Privacy Policy and Terms and Conditions.

Essential cookies

These cookies are necessary for core functionality, such as security, your shopping cart, remembering your cookie choice, and your progress through a report or free-trial request you started. They always need to be on.

Analytics cookies

We use analytics cookies to understand how visitors use the site — the pages visited, time spent, and where visitors came from.

Marketing cookies

These help us measure how effective our advertising is, such as recording actions you take after clicking one of our ads. If you don't enable this, you may still see our ads, but they won't be measured this way.

Support

Hi! How can we help you today?

Loading…